{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-001035","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2023-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.506929+00:00","generated_at":"2026-06-13T16:06:37.302004+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aldeyra Phase 2 ADX-629 in chronic cough meets primary safety endpoint; cough frequency significantly reduced vs placebo","bullets":["Awake cough frequency reduced vs placebo (P=0.01); 24-hr cough frequency (P=0.001).","ADX-629 well tolerated; no serious adverse events or discontinuations reported.","51 patients enrolled, all completed both treatment periods in crossover design.","Improvement in LDL and HDL levels observed consistent with prior trials.","Company to discuss results with regulators; Phase 2 trials in atopic dermatitis and other indications expected 2H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-001035","json":"https://secwatch.observer/filing/0001157523-23-001035.json","markdown":"https://secwatch.observer/filing/0001157523-23-001035.md","text":"https://secwatch.observer/filing/0001157523-23-001035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000115752323001035/0001157523-23-001035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000115752323001035/a53433819.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T16:06:37.302004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}